Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HRTX Heron Therapeutics	$1.39 +4.9%	$1.87	$1.04 ▼ $2.68	$212.15M	1.15	1.68 million shs	866,361 shs
MAIA MAIA Biotechnology	$1.57 +2.6%	$1.70	$1.40 ▼ $3.74	$51.79M	0.01	325,622 shs	33,971 shs
OGI Organigram Global	$1.61 +2.2%	$1.43	$0.85 ▼ $2.05	$215.15M	1.45	726,762 shs	406,908 shs
VYGR Voyager Therapeutics	$3.46 +3.1%	$3.26	$2.64 ▼ $8.27	$191.65M	0.9	527,214 shs	191,272 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HRTX Heron Therapeutics	+1.54%	-2.22%	-30.53%	-28.65%	-33.33%
MAIA MAIA Biotechnology	-3.16%	-1.92%	-8.38%	-10.53%	-48.31%
OGI Organigram Global	+4.67%	+0.64%	+1.29%	+14.60%	-22.28%
VYGR Voyager Therapeutics	+0.30%	-9.68%	+6.33%	+15.07%	-51.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HRTX Heron Therapeutics	4.1857 of 5 stars	3.2	1.0	4.2	3.6	3.3	0.6
MAIA MAIA Biotechnology	1.2725 of 5 stars	0.0	3.0	0.0	3.0	3.3	0.0
OGI Organigram Global	0.4048 of 5 stars	0.0	2.0	0.0	1.4	0.0	1.3
VYGR Voyager Therapeutics	3.371 of 5 stars	3.6	1.0	4.6	0.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HRTX Heron Therapeutics	2.33	Hold	$4.50	224.91% Upside
MAIA MAIA Biotechnology	0.00	N/A	N/A	N/A
OGI Organigram Global	0.00	N/A	N/A	N/A
VYGR Voyager Therapeutics	3.13	Buy	$13.25	282.42% Upside

Current Analyst Ratings Breakdown

Latest MAIA, OGI, HRTX, and VYGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/8/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
8/7/2025	VYGR Voyager Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HRTX Heron Therapeutics	$144.29M	1.47	N/A	N/A	($0.18) per share	-7.69
MAIA MAIA Biotechnology	N/A	N/A	N/A	N/A	$0.12 per share	N/A
OGI Organigram Global	$117.47M	1.83	N/A	N/A	$2.08 per share	0.77
VYGR Voyager Therapeutics	$42.58M	4.51	N/A	N/A	$4.40 per share	0.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HRTX Heron Therapeutics	-$13.58M	-$0.02	N/A	N/A	N/A	-0.62%	N/A	-0.40%	N/A
MAIA MAIA Biotechnology	-$23.25M	-$1.38	N/A	N/A	N/A	N/A	-497.29%	-165.42%	N/A
OGI Organigram Global	-$33.39M	$0.05	32.11	N/A	N/A	2.86%	-8.19%	-5.79%	N/A
VYGR Voyager Therapeutics	-$65M	-$1.85	N/A	N/A	N/A	-253.49%	-37.65%	-28.89%	N/A

Latest MAIA, OGI, HRTX, and VYGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q3 2025	OGI Organigram Global	-$0.01	-$0.03	-$0.02	-$0.03	$68.04 million	$50.49 million
8/8/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	-$0.02	-$0.01	-$0.02	$38.08 million	$37.20 million
8/6/2025	Q2 2025	VYGR Voyager Therapeutics	-$0.48	-$0.57	-$0.09	-$0.57	$9.50 million	$5.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
MAIA MAIA Biotechnology	N/A	N/A	N/A	N/A	N/A
OGI Organigram Global	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HRTX Heron Therapeutics	N/A	0.82	0.53
MAIA MAIA Biotechnology	N/A	2.19	2.19
OGI Organigram Global	N/A	2.59	1.42
VYGR Voyager Therapeutics	N/A	5.43	5.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HRTX Heron Therapeutics	80.01%
MAIA MAIA Biotechnology	5.65%
OGI Organigram Global	34.63%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
HRTX Heron Therapeutics	5.86%
MAIA MAIA Biotechnology	32.32%
OGI Organigram Global	0.09%
VYGR Voyager Therapeutics	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HRTX Heron Therapeutics	300	153.29 million	144.31 million	Optionable
MAIA MAIA Biotechnology	9	32.99 million	22.33 million	Not Optionable
OGI Organigram Global	860	134.05 million	133.93 million	Optionable
VYGR Voyager Therapeutics	100	55.47 million	51.93 million	Optionable

MAIA, OGI, HRTX, and VYGR Headlines

Recent News About These Companies

Voyager Therapeutics Extends Cash Runway to 2028

August 13, 2025 | msn.com

Research Analysts Offer Predictions for VYGR Q3 Earnings

August 12, 2025 | americanbankingnews.com

Truist Financial Keeps Their Buy Rating on Voyager Therapeutics (VYGR)

August 11, 2025 | theglobeandmail.com

Voyager Therapeutics (VYGR) Receives a Buy from Oppenheimer

August 11, 2025 | theglobeandmail.com

Equities Analysts Offer Predictions for VYGR Q3 Earnings

August 11, 2025 | marketbeat.com

Voyager Therapeutics (NASDAQ:VYGR) Releases Earnings Results, Misses Estimates By $0.09 EPS

August 10, 2025 | marketbeat.com

Voyager Therapeutics (VYGR) Receives a Buy from Canaccord Genuity

August 9, 2025 | theglobeandmail.com

Voyager Therapeutics (NASDAQ:VYGR) Price Target Lowered to $8.00 at Wedbush

August 8, 2025 | marketbeat.com

Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Voyager Reports Second Quarter 2025 Financial and Operating Results

August 6, 2025 | globenewswire.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of "Buy" by Analysts

July 30, 2025 | marketbeat.com

Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Tuesday

July 29, 2025 | marketbeat.com

Voyager 1 and 2: From Earth to Interstellar Space: The Final Frontier Awaits

July 21, 2025 | msn.com

Read the NASA ‘Voyager Declaration’ Letter of Dissent

July 21, 2025 | nytimes.com

Mascarene Partners Acquires Voyager Trucking

July 18, 2025 | finance.yahoo.com

Voyager Therapeutics adds new gene therapy to Alzheimer’s program

July 18, 2025 | bioworld.comB

Mascarene buys US waste services company Voyager Trucking

July 18, 2025 | realassets.ipe.comR

Mascarene to acquire waste services transport firm Voyager Trucking Corporation

July 18, 2025 | pehub.com

Looking Beyond Voyager 1 And 2

July 17, 2025 | msn.com

Robert Beltran on Star Trek: I “Risked being fired” Because I Didn’t Like What Was Happening in the Last 3 Years of Voyager

July 16, 2025 | fandomwire.comF

Uranus Heat Readings Contradict 40-Year-Old Voyager 2 Results

July 16, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MAIA, OGI, HRTX, and VYGR Company Descriptions

Heron Therapeutics NASDAQ:HRTX

$1.38 +0.07 (+4.92%)

As of 11:15 AM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

MAIA Biotechnology NYSEAMERICAN:MAIA

$1.57 +0.04 (+2.61%)

As of 11:13 AM Eastern

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Organigram Global NASDAQ:OGI

$1.60 +0.04 (+2.23%)

As of 11:15 AM Eastern

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

Voyager Therapeutics NASDAQ:VYGR

$3.46 +0.10 (+3.10%)

As of 11:15 AM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time